NCT04514484 2026-03-23Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNational Cancer Institute (NCI)Phase 1 Active not recruiting8 enrolled
NCT01639508 2025-12-17Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityMemorial Sloan Kettering Cancer CenterPhase 2 Recruiting86 enrolled
NCT01708954 2025-11-28Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting125 enrolled 12 charts
NCT03170960 2025-08-17Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsExelixisPhase 1 Active not recruiting914 enrolled